{"title":"Disrupting Paraspeckle Stability by Targeting WTX-NONO Phase Separation Enhances Chemotherapy Efficacy in Gastric Cancer.","authors":"Yangwei Xu,Zaisheng Ye,Zhihao Lin,Xuexia Qian,Yanyan Li,Fei Sun,Zetao Chen,Zhangting Zhao,Junping Bai,Meihang Du,Yi-Chuan Li,Xuanqi Li,Lijun Han,Huanhu Zhang,Mien-Chie Hung,Liwei An,Qingling Zhang","doi":"10.1158/0008-5472.can-25-1747","DOIUrl":null,"url":null,"abstract":"Nuclear paraspeckles play critical roles in orchestrating gene transcription to support tumor development and progression. Elucidating regulators of their dynamic compositions and formation could provide potential targets for treating cancer. Here, we discovered that the short isoform of WTX (WTX-S) specifically disrupted paraspeckle stability. WTX-S selectively interacted with and sequestered NONO (also as p54nrb) from paraspeckles. Mechanistically, interaction between WTX-S and NONO induced formation of nuclear bodies via liquid-liquid phase separation (WTX-NBs). The coiled-coil domain 2 (WTX-CCD2) directly interacted with NONO-CCD to compartmentalize paraspeckle proteins and subsequently disrupt paraspeckle stability. Functionally, the paraspeckle disintegration induced by WTX-NBs resulted in enhanced chemotherapy sensitivity and favorable prognosis in gastric cancer (GC). Importantly, the cell-penetrating synthetic peptide WTXAP, based on the WTX-NONO interface, mimicked WTX-NB-mediated paraspeckle disintegration and exhibited potent antitumor activity. Likewise, treatment with KPT-330, an FDA-approved XPO1 inhibitor, significantly increased the extent of WTX-S-mediated paraspeckle disintegration, sensitizing WTXhigh GC to chemotherapy. Collectively, these findings characterized the function and potential clinical significance of WTX-NBs, offering a strategy for sensitizing GC to chemotherapy.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"15 1","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/0008-5472.can-25-1747","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Nuclear paraspeckles play critical roles in orchestrating gene transcription to support tumor development and progression. Elucidating regulators of their dynamic compositions and formation could provide potential targets for treating cancer. Here, we discovered that the short isoform of WTX (WTX-S) specifically disrupted paraspeckle stability. WTX-S selectively interacted with and sequestered NONO (also as p54nrb) from paraspeckles. Mechanistically, interaction between WTX-S and NONO induced formation of nuclear bodies via liquid-liquid phase separation (WTX-NBs). The coiled-coil domain 2 (WTX-CCD2) directly interacted with NONO-CCD to compartmentalize paraspeckle proteins and subsequently disrupt paraspeckle stability. Functionally, the paraspeckle disintegration induced by WTX-NBs resulted in enhanced chemotherapy sensitivity and favorable prognosis in gastric cancer (GC). Importantly, the cell-penetrating synthetic peptide WTXAP, based on the WTX-NONO interface, mimicked WTX-NB-mediated paraspeckle disintegration and exhibited potent antitumor activity. Likewise, treatment with KPT-330, an FDA-approved XPO1 inhibitor, significantly increased the extent of WTX-S-mediated paraspeckle disintegration, sensitizing WTXhigh GC to chemotherapy. Collectively, these findings characterized the function and potential clinical significance of WTX-NBs, offering a strategy for sensitizing GC to chemotherapy.
期刊介绍:
Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research.
With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445.
Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.